Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Consumer Services and Basic Materials sectors led shares higher. At the close in... Gainers: CNET ...

Shares of the British-Swedish pharmaceutical titan AstraZeneca are trading 7% lower in London today as investors price in the acquisition of Alexion Pharmaceuticals for $39 billion. A deal, which is ...

Alexion Pharmaceuticals (NASDAQ:ALXN) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in ...

(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ...

Efzimfotase alfa is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Hypophosphatasia. According to GlobalData, Phase III drugs for Hypophosphatasia have a 100% ...

(IN BRIEF) Anders Svensson has been appointed as Hexagon’s new President and CEO, set to take office by July 2025. He will succeed Norbert Hanke, who will continue as interim President and CEO until ...

Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in ...

The Symbol Digit Modalities Test (SDMT), California Verbal Learning Test—II (CVLT ... She has received personal compensation for consulting from Alexion, Biogen, EMD Serono, Jansen, Novartis, Roche ...